Cidara Therapeutics Inc [CDTX] stock is trading at $26.88, up 6.46%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CDTX shares have gain 14.87% over the last week, with a monthly amount glided 33.00%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cidara Therapeutics Inc [NASDAQ: CDTX] stock has seen the most recent analyst activity on December 13, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $34. Previously, Guggenheim started tracking the stock with Buy rating on November 08, 2024, and set its price target to $33. On August 14, 2024, upgrade upgraded it’s rating to Buy but maintained its price target of $24 on the stock. WBB Securities upgraded its rating to a Strong Buy but $6.25 remained the price target by the analyst firm on September 22, 2021. Aegis Capital started tracking with a Buy rating for this stock on March 04, 2021, and assigned it a price target of $9. In a note dated September 04, 2019, Wedbush upgraded an Outperform rating on this stock and boosted its target price from $2 to $4.
Cidara Therapeutics Inc [CDTX] stock has fluctuated between $10.00 and $25.32 over the past year. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $26.88 at the most recent close of the market. An investor can expect a potential drop of -55.36% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 26.35M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -1.72%, Pretax Profit Margin comes in at -4.77%, and Net Profit Margin reading is -4.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.74, Equity is -2.19 and Total Capital is -0.38.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 25.51 points at the first support level, and at 24.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 27.84, and for the 2nd resistance point, it is at 28.81.
Ratios To Look Out For
For context, Cidara Therapeutics Inc’s Current Ratio is 3.54. Further, the Quick Ratio stands at 3.54, while the Cash Ratio is 2.87. Considering the valuation of this stock, the price to sales ratio is 7.19, the price to book ratio is 1.64.
Transactions by insiders
Recent insider trading involved Sandison Taylor, Chief Medical Officer, that happened on Sep 11 ’24 when 924.0 shares were sold. CHIEF SCIENTIFIC OFFICER, Tari Leslie completed a deal on Sep 11 ’24 to sell 909.0 shares. Meanwhile, President & CEO Stein Jeffrey bought 8000.0 shares on Jun 07 ’24.
